Clinical Trials Directory

Trials / Completed

CompletedNCT06462313

Dobutamine for Management of Surgical Patients With Septic Shock

Director, Head of Anesthesiology and Critical Care, Principal Investigator, Professor

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
584 (actual)
Sponsor
First Affiliated Hospital of Zhejiang University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Septic shock is the last and most severe stage of sepsis and is defined by extremely low blood pressure, despite lots of intravenous fluids. The incidence of septic shock related cardiomyopathy was 10% to 70%. Besides, general anesthesia will inhibit the sympathetic nervous system, reduce myocardial contractility and aggravate cardiac dysfunction. No randomized controlled trials have yet explore the effects of dobutamine on clinical outcomes for patients with septic shock undergoing surgery under general anesthesia.

Detailed description

Sepsis, defined as life-threatening organ dysfunction, is caused by a dysregulated host response to infection, which 30-day mortality rate is about 24.4%. Septic shock is the last and most severe stage of sepsis and is defined by extremely low blood pressure, despite lots of intravenous fluids. Surgical patients with septic shock are not rare. The incidence of septic shock related cardiomyopathy was 10% to 70%. Besides, general anesthesia will inhibit the sympathetic nervous system, reduce myocardial contractility and aggravate cardiac dysfunction, furthermore exacerbate hemodynamic instability, and then increase the incidence of AKI and patient mortality. Therefore, to improve cardiac function in patients with septic shock who received general anesthesia is the key to save patients life and improve prognosis. The latest international guidelines for the treatment of septic shock recommend - in patients with septic shock combined with cardiac dysfunction, treatment with norepinephrine in combination with dobutamine is recommended if inadequate tissue perfusion persists after adequate fluid resuscitation and maintenance of blood pressure, but the level of evidence is weak. Dobutamine acts on β-adrenergic receptors, which can improve tissue perfusion, and small doses of 2.5-5ug/kg/min can increase myocardial contractility and improve cardiac function in patients without increasing heart rate. Previous study has demonstrated that the combined use of norepinephrine and dobutamine can elevate left ventricular ejection fraction, cardiac index, improve tissue perfusion, and reduce mortality in patients with septic shock. No randomized controlled trials have yet explore the effects of dobutamine on clinical outcomes for patients with septic shock undergoing surgery under general anesthesia.

Conditions

Interventions

TypeNameDescription
DRUGDobutaminePatients with septic shock in Dobutamine group will be initiated on Dobutamine at 5 mcg/kg/min when electrocardiogram, invasive blood pressure, and oxygen saturation were monitored.
DRUGNorepinephrineNorepinephrine was titrated to maintain a mean arterial pressure at 65mmHg or more in both groups.

Timeline

Start date
2024-06-18
Primary completion
2025-11-15
Completion
2025-11-15
First posted
2024-06-17
Last updated
2025-12-04

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06462313. Inclusion in this directory is not an endorsement.